Immutep touts mid-stage data for LAG-3 drug in first-line NSCLC, finalizing plans for PhIII test: #ESMO23
MADRID — Immutep unveiled additional data at ESMO from a Phase II trial studying a LAG-3 drug designed to help certain non-small cell lung cancer patients potentially do away with chemotherapy.
The biotech is finalizing plans for a Phase III trial for the first half of 2024 based on these results and after raising $53 million in June. The Phase II TACTI-002 study combines eftilagimod alpha — efti for short — with Merck’s Keytruda in first-line unresectable or metastatic NSCLC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.